The Role of Droperidol in the Management of Acute Agitation: A Comprehensive Review
BACKGROUND: Acute behavioral disturbance accounts for ~1.7 million emergency department visits in the USA annually, with 83% involving an underlying serious mental illness. A 2001 FDA black box warning regarding QT prolongation reduced use of droperidol, a butyrophenone antipsychotic, but recent data challenge these concerns. METHODS: We reviewed randomized controlled trials, systematic reviews, and observational studies from 2000 to 2025 assessing droperidol's efficacy and safety. RESULTS: Droperidol provides rapid, effective sedation, with onset within 3 to 10 minutes and median time to adequate sedation of 14 to 25 minutes. Sixty-four percent of patients achieved adequate sedation at 15 minutes with droperidol versus 25% to 35% with ziprasidone and 29% with lorazepam. QT prolongation occurred in 1.3% of 1009 patients, mostly those with pre-existing risk factors. Respiratory depression was less common with droperidol (12%) than with ziprasidone (36% to 39%) or lorazepam (48%). Droperidol-midazolam combinations achieved faster sedation and reduced need for rescue medications (41% vs. 62%). Droperidol-treated patients had shorter hospital stays. Large studies found negligible rates of torsades de pointes or extracardiac arrhythmias. Elderly and pediatric patients responded favorably to low-dose droperidol. The American College of Emergency Physicians now recommends droperidol as first-line treatment for severe agitation. Combined with benzodiazepines, droperidol shows synergistic effects and allows lower doses of both with fewer adverse effects. CONCLUSIONS: Recent evidence contradicts earlier FDA concerns, supporting droperidol as a safe, effective treatment for acute agitation. Its rapid onset, efficacy, safety profile, and operational benefits, including shorter ED stay, support its return to routine clinical practice.
Authors
- Zeeshan Mansuri (ORCID: https://orcid.org/0000-0002-7232-6136)
- Garima Yadav (ORCID: https://orcid.org/0000-0001-9517-3542)
- Sreshta Jeelugu
- Malav Patel (ORCID: https://orcid.org/0009-0004-2386-8248)
- Srajan Gupta
- Shivani Malavia
- Hetansh Shah (ORCID: https://orcid.org/0009-0001-6739-4388)
Institutions
- New York Medical College (US)
- Yale University (US)
- Gujarat Cancer Society (IN)
- Sri Venkateswara Medical College and Ruia Hospital (IN)
- Government Medical College (IN)
- Yale New Haven Health System (US)
- GCS Medical College (IN)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1097/jcp.0000000000002292
- Primary Topic
- Anesthesia and Sedative Agents
- Type
- article
- Field-Weighted Citation Impact
- 0.00